Natco Pharma has delivered an impressive 40% return in just 12 weeks, climbing from ₹726 to ₹1,000. With improving financials and strong trading volumes, the stock continues to show sustained momentum.

Natco Pharma Limited, headquartered in Hyderabad, was established in 1981 with an initial capital of ₹3.3 million. The company is a prominent Indian pharmaceutical player engaged in the production of active pharmaceutical ingredients (APIs) and finished dosage formulations. Its business operations span multiple segments, including bulk chemicals, finished formulations, retail pharmacy, and contract manufacturing (job work).

Natco Pharma Why declined in Sep 2024 from ₹1639 to ₹726

Suzlon is next GEM in Renewable Energy , Price Trend up , Surging Monthly volume

In the oncology space, Natco offers a wide range of products such as Desifer, Veenat, Bendit, Bortenat, Lenalid, and Clokeran. In the broader pharmaceutical segment, its key offerings include T-Score, PT-MaX, Glatimer, Tarana, and Tigi.

Company Performance

Stock 52W low ₹726 ,52W High ₹1639 with market capitalization of ₹ 17885 Cr and PE 9.49 and Sector PR 39.22

Net Revenue collection in Q4 FY2025 stood at ₹1,287 crore, compared to ₹1,110 crore in Q4 FY2024.

Net profit rose to ₹406 crore in Q4 FY2025, up from ₹386 crore in the same quarter of the previous financial year.

Union Cabinet Unleashes 1Lac Crore for Innovation & R&D -Sunrise Sectors -Artificial intelligence, Petrochemical, Sports Industry, Auto Parts Industry, Capital Goods Production, Defence Manufacturing , Leather Goods Production, Banking, Fintech & Financial Services, Automobile Production and any more are under innovation.

Reserve & Surplus

Natco Pharma has shown a consistent upward trend over the past three years, reflecting the company’s strong financial position and earnings retention.

FY2025: ₹7,571 crore

FY2024: ₹5,817 crore

FY2023: ₹4,837 crore

Gross Profit and Operating Margin

Natco Pharma has delivered the marvelous performance in last three year which shows the strength and confidence by investors in the Company.

Gross Profit Margin % Excellent Performance

FY2025: 57.57

FY2024: 47.00

FY2023: 38.42

Operating Margin % Robust Delivery

FY2025: 57.27

FY2024: 42.33

FY2023: 32.37

Natco Pharma delivered the good performance continuous improvement in performance and progress Export-focused auto and pharma stocks saw notable gains on July 3, driven by market optimism over a potential India-US trade deal expected to be announced soon.

Disclaimer

The information provided on this website is for educational and informational purposes only and should not be considered as financial, investment, or trading advice. All content, including stock analyses, market data, and opinions, is based on publicly available information believed to be accurate at the time of publication.

Stock price surged 60% in last 20 weeks , In Feb stock was trading at ₹ 2131 and reached to ₹ 3775 in May, delivered a robust growth, Mazagon Dock Acquire Colombo Dockyard